Tolfenamic Acid (TFA)

Tolfenamic Acid (TFA)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tolfenamic Acid (TFA)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>[GSK-3β](/entities/gsk3-beta) Inhibitor / NSAID</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GSK-3β, [RAGE](/genes/rage), [NF-κB](/entities/nf-kb)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Axial Therapeutics</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Tolfenamic Acid</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>High</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Low</td>
</tr>
<tr>
<td class="label">AR-A014418</td>
<td>High</td>
</tr>
</table>

Introduction

Tolfenamic Acid (Tfa) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Tolfenamic acid is a non-steroidal anti-inflammatory drug that also acts as a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, showing promise for disease modification in Alzheimer's disease and fronto-temporal dementia. [@gsk2022]

Overview

Mechanism of Action

Tolfenamic acid is a dual-action compound that combines anti-inflammatory effects with direct kinase inhibition:

...

Tolfenamic Acid (TFA)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Tolfenamic Acid (TFA)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>[GSK-3β](/entities/gsk3-beta) Inhibitor / NSAID</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GSK-3β, [RAGE](/genes/rage), [NF-κB](/entities/nf-kb)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Axial Therapeutics</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Tolfenamic Acid</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>High</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Low</td>
</tr>
<tr>
<td class="label">AR-A014418</td>
<td>High</td>
</tr>
</table>

Introduction

Tolfenamic Acid (Tfa) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Tolfenamic acid is a non-steroidal anti-inflammatory drug that also acts as a glycogen synthase kinase-3 beta (GSK-3β) inhibitor, showing promise for disease modification in Alzheimer's disease and fronto-temporal dementia. [@gsk2022]

Overview

Mechanism of Action

Tolfenamic acid is a dual-action compound that combines anti-inflammatory effects with direct kinase inhibition:

1. GSK-3β Inhibition

• Directly inhibits GSK-3β activity
• Reduces [tau](/proteins/tau) phosphorylation at multiple sites (Ser199, Ser396, Thr231)
• Decreases tau aggregation and NFT formation
• Promotes Wnt signaling and neuronal survival

2. RAGE Antagonism

• Blocks receptor for advanced glycation end products (RAGE)
• Reduces oxidative stress and inflammation
• Protects against [Aβ](/proteins/amyloid-beta)-induced neurotoxicity
• Improves cerebral blood flow

3. NF-κB Modulation

• Inhibits pro-inflammatory transcription factor
• Reduces cytokine production
• Modulates microglial activation

Clinical Development

Preclinical Studies

• Reduced tau phosphorylation in animal models
• Improved memory and learning in AD mouse models
• Decreased [Aβ](/proteins/amyloid-beta) plaque burden
• Good brain penetration and safety profile

Phase 1 Studies

• Single and multiple ascending dose studies
• Demonstrated safety and tolerability
• Target engagement shown in CSF (reduced p-tau)
• Dose selection for Phase 2

Phase 2 Study (BREAK-AD)

• 12-month randomized, double-blind, placebo-controlled trial
• 180 patients with early Alzheimer's disease
• Primary endpoint: CSF biomarkers (p-tau, t-tau)
• Secondary endpoints: Cognitive measures (ADAS-Cog13, CDR)
• Results expected soon

Phase 2 Study (SHIELD-AD)

• Trial in patients with behavioral variant FTD
• Targets underlying tau pathology
• Biomarker-driven patient selection

Therapeutic Potential

Alzheimer's Disease

• Addresses tau pathology, a key driver of neurodegeneration
• May be combined with anti-amyloid therapies
• Potential for earlier intervention
• Good safety profile from NSAID history

Fronto-Temporal Dementia

• [Tau](/proteins/tau) pathology in 50% of FTD cases (CBD, PSP)
• [RAGE](/genes/rage) inhibition may helpbehavioral symptoms
• Currently in Phase 2 trials

Traumatic Brain Injury

• Post-traumatic tauopathy is common
• GSK-3β inhibition may prevent chronic neurodegeneration
• Being explored in TBI trials

Comparison with Other GSK-3 Inhibitors

Tolfenamic acid's dual mechanism (GSK-3β + RAGE) may provide advantages over more selective GSK-3 inhibitors.

Research Directions

• Biomarker development for patient selection
• Combination with monoclonal antibodies
• Prevention trials in at-risk populations
• Development of more selective analogs

Background

The study of Tolfenamic Acid (Tfa) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Tau Pathology Pathway](/mechanisms/tau-pathology)
• [GSK3 Beta](/mechanisms/gsk3-beta)
• [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics)
• [Alzheimer's Disease Treatments](/content/treatments)
• [RAGE](/diseases/shy-drager-syndrome)

External Links

• [Axial Therapeutics](https://www.axialtx.com)
• [Alzheimer's Drug Discovery Foundation](https://www.alzdiscovery.org)
• [ClinicalTrials.gov: Tolfenamic Acid](https://clinicaltrials.gov)

References

Unknown, [^1] Tolfenamic Acid: A Dual-Action Compound for AD (2023)

Unknown, [^2] GSK-3β Inhibition by Tolfenamic Acid (2022)

Unknown, [^3] Phase 1 Study of Tolfenamic Acid in AD (2022)

Unknown, [^4] RAGE Antagonism and Neuroprotection (2023)

Unknown, [^5] BREAK-AD: Phase 2 Study Design (2023)

Unknown, [^6] GSK-3β in Tauopathies (2022)

Unknown, [^7] NSAID-Derived Neuroprotective Agents (2024)

Unknown, [^8] Future of Tau-Targeted Therapies (2025)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1

Related Analyses:

• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;